Association between C3orf21, TP63 polymorphisms and environment and NSCLC in never-smoking Chinese population

Gene

Volumn 497, Issue 1, 2012, Pages 93-97

  Zhang, Yongjun ^a   Gu, Cuiping ^a   Shi, Hua ^a   Zhang, Aiqin ^a   Kong, Xiangming ^a   Bao, Wenlong ^a   Deng, Dehou ^a   Ren, Lili ^a   Gu, Danlin ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

C3orf21; Chinese; Environment; Genetic polymorphism; Non small cell lung cancer; TP63

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84862802252     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.01.053     Document Type: Article

References (70)

1. Achary A., Das I., Chandhok D., Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid. Med. Cell Longevita 2010, 3:23-34.
2. Ariyoshi N., Miyamoto M., Umetsu Y., Kunitoh H., Dosaka-Akita H., Sawamura Y., et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomark. Prev. 2002, 11:890-894.
3. Boffetta P. Human cancer from environmental pollutants: the epidemiological evidence. Mutat. Res. 2006, 608:157-162.
4. Boldrup L., Coates P.J., Gu X., Nylander K. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J. Pathol. 2007, 213:384-391.
5. Choi H.R., Batsakis J.G., Zhan F., Sturgis E., Luna M.A., El-Naggar A.K. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum. Pathol. 2002, 33:158-164.
6. Cianchi F., Cortesini C., Bechi P., Fantappiè O., Messerini L., Vannacci A., et al. Upregulation of COX-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001, 121:1339-1347.
7. Crook T., Nicholls J.M., Brooks L., O'Nions J., Allday M.J. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?. Oncogene 2000, 19:3439-3444.
8. Cui R., He J., Mei R., de Fromentel C.C., Martel-Planche G., Taniere P., et al. Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus. Biochem. Biophys. Res. Commun. 2005, 336:339-345.
9. Daigo Y., Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen. Thorac. Cardiovasc. Surg. 2008, 56:43-53.
10. De-Marzo A., Platz E., Sutcliffe S., Xu J., Grönberg H., Drake C.G., et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007, 7:256-269.
11. DeYoung M.P., Johannessen C.M., Leong C.O., Faquin W., Rocco J.W., Ellisen L.W. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res. 2006, 66:9362-9368.
12. DiCostanzo A., Festa L., Duverger O., Vivo M., Guerrini L., La Mantia G., et al. Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation. Cell Cycle 2009, 8:1185-1195.
13. Dong J., Dai J., Shu Y., Pan S., Xu L., Chen W., et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 2010, 31:1080-1086.
14. Edward A. Ratovitski LKB1/PEA3/δNp63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure. Oxidative Medicine and Cellular Longevity 2010, 3:317-324.
15. Essick E.E., Flora Sam F. Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer. Oxid. Med. Cell Longevita 2010, 3:168-177.
16. Finlan L.E., Hupp T.R. p63: the phantom of the tumor suppressor. Cell Cycle 2007, 6:1062-1071.
17. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005, 7:363-373.
18. Flores E.R. The roles of p63 in cancer. Cell Cycle 2007, 6:300-304.
19. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416:560-564.
20. Guo X., Keyes W.M., Papazoglu C., Zuber J., Li W., Lowe S.W., et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat. Cell Biol. 2009, 11:1451-1457.
21. Hainaut P. Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus. Biochem. Biophys. Res. Commun. 2005, 336:339-345.
22. Hibi K., Trink B., Patturajan M., Westra W.H., Caballero O.L., Hill D.E., et al. AIS (p63) is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5462-5467.
23. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91:1194-1210.
24. Hsiao Y.H., Su Y.A., Tsai H.D., Mason J.T., Chou M.C., Man Y.G. Increased invasiveness and aggressiveness in breast epithelia with cytoplasmic p63 expression. Int. J. Biol. Sci. 2010, 6:428-442.
25. Hu H., Xia S.H., Li A.D., Xu X., Cai Y., Han Y.L., et al. Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int. J. Cancer 2002, 102:580-583.
26. Hu Z., Wu C., Shi Y., Guo H., Zhao X., Yin Z., et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat. Genet. 2010, 43:792-796.
27. Iizasa T., Baba M., Saitoh Y., Suzuki M., Haga Y., Iyoda A., et al. A polymorphism in the 5'-flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population. Oncol. Rep. 2005, 14:919-923.
28. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
29. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
30. Jorgensen E.D., Zhao H., Traganos F., Albino A.P., Darzynkiewicz Z. DNA damage response induced by exposure of human lung adenocarcinoma cells to smoke from tobacco- and nicotine-free cigarettes. Cell Cycle 2010, 9:2170-2176.
31. Kang J.U., Koo S.H., Kwon K.C., Park J.W., Kim J.M. Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 2009, 9:237.
32. Karen S.K., Christopher A.L. Genetic and environmental influences on malformations of the cardiac outflow tract. Expert Rev. Cardiovasc. Ther. 2005, 3:1125-1130.
33. Kim J.H., Dhanasekaran S.M., Mehra R., Tomlins S.A., Gu W., Yu J., et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res. 2007, 67:8229-8239.
34. Koster M.I., Lu S.L., White L.D., Wang X.J., Roop D.R. Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. Cancer Res. 2006, 66:3981-3986.
35. Lee J.M., Yanagawa J., Peebles K.A., Sharma S., Mao J.T., Dubinett S.M. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit. Rev. Oncol. Hematol. 2008, 66:208-217.
36. Lin M., Smith L.T., Smiraglia D.J., Kazhiyur-Mannar R., Lang J.C., Schuller D.E., et al. DNA copy number gains in head and neck squamous cell carcinoma. Oncogene 2006, 25:1424-1433.
37. Lin Y.L., Sengupta S., Gurdziel K., Bell G.W., Jacks T., Flores E.R. p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet. 2009, 5:e1000680.
38. Liu G., Zhou W., Christiani D.C. Molecular epidemiology of non-small cell lung cancer. Semin. Respir. Crit. Care Med. 2005, 26:265-272.
39. Maiese K. Marking the onset of oxidative stress: Biomarkers and novel strategies. Oxid. Med. Cell Longevita 2009, 2:1.
40. Maiuri M.C., Tasdemir E., Criollo A., Morselli E., Vicencio J.M., Carnuccio R., et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 2009, 16:87-93.
41. Malaguarnera R., Vella V., Vigneri R., Frasca F. p53 family proteins in thyroid cancer. Endocr. Relat. Cancer 2007, 14:43-60.
42. Massion P.P., Taflan P.M., Jamshedur Rahman S.M., Yildiz P., Shyr Y., Edgerton M.E., et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003, 63:7113-7121.
43. Miki D., Kubo M., Takahashi A., Yoon K.A., Kim J., Lee G.K., et al. Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat. Genet. 2010, 42:893-897.
44. Moling J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83:584-594.
45. Murray-Zmijewski F., Lane D.P., Bourdon J.C. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006, 13:962-972.
46. Nie Q., Yang X.N., An S.J., Zhang X.C., Yang J.J., Zhong W.Z., et al. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Eur. J. Cancer 2011, 47:1962-1970.
47. Ory B., Ramsey M.R., Wilson C., Vadysirisack D.D., Forster N., Rocco J.W., et al. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J. Clin. Invest. 2001, 121:809-820.
48. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
49. Patturajan M., Nomoto S., Sommer M., Fomenkov A., Hibi K., Zangen R., et al. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002, 1:369-379.
50. Rocco J.W., Leong C.O., Kuperwasser N., DeYoung M.P., Ellisen L.W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006, 9:45-56.
51. Romano R.A., Birkaya B., Sinha S. A functional enhancer of keratin14 is a direct transcriptional target of deltaNp63. J. Invest. Dermatol. 2007, 127:1175-1186.
52. Romano R.A., Ortt K., Birkaya B., Smalley K., Sinha S. An active role of the DeltaN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One 2009, 4:e5623.
53. Sasaki H., Okuda K., Takada M., Kawahara M., Kitahara N., Matsumura A., et al. A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. J. Cancer Res. Clin. Oncol. 2008, 134:1371-1376.
54. Sniezek J.C., Matheny K.E., Westfall M.D., Pietenpol J.A. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004, 114:2063-2072.
55. Song N., Tan W., Xing D., Lin D. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 2001, 22:11-16.
56. Su X., Paris M., Gi Y.J., Tsai K.Y., Cho M.S., Lin Y.L., et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 2009, 5:64-75.
57. Tan W., Chen G.F., Xing D.Y., Song C.Y., Kadlubar F.F., Lin D.X. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer 2001, 95:96-101.
58. Thurfjell N., Coates P.J., Uusitalo T., Mahani D., Dabelsteen E., Dahlqvist A., et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int. J. Oncol. 2004, 25:27-35.
59. Thurfjell N., Coates P.J., Vojtesek B., Benham-Motlagh P., Eisold M., Nylander K. Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int. J. Mol. Med. 2005, 16(6):1065-1070.
60. Tomkova K., Tomka M., Zajac V. Contribution of p53, p63, and p73 to the developmental diseases and cancer. Neoplasma 2008, 55:177-181.
61. Truong A.B., Kretz M., Ridky T.W., Kimmel R., Khavari P.A. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev. 2006, 20:3185-3197.
62. Tonon G., Wong K.K., Maulik G., Brennan C., Feng B., Zhang Y., et al. High-resolution genomic profiles of human lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9625-9630.
63. Vousden K.H., Prives C. Blinded by the light: The growing complexity of p53. Cell 2009, 137:413-431.
64. Walter R., Gottlieb D.J., O'Connor G.T. Environmental and genetic risk factors and gene-environment interactions in the pathogenesis of chronic obstructive lung disease. Environ. Health Perspect. 2000, 108(Suppl. 4):733-742.
65. Wu J., Bergholz J., Lu J., Sonenshein G.E., Xiao Z.X. TAp63 Is a Transcriptional Target of NF-κB. J. Cell. Biochem. 2010, 109:702-710.
66. Yang S.R., Chida A.S., Bauter M.R., Shafiq N., Seweryniak K., Maggirwar S.B., et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-κB and posttranslational modifications of histone deacetylase in macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 291:46-57.
67. Yao H., Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr. Opin. Pharmacol. 2009, 9:375-383.
68. Yin W., Ye X., Shi L., Wang Q.K., Jin H., Wang P., et al. TP63 Gene Mutations in Chinese P63 Syndrome Patients. J. Dent. Res. 2010, 89:813-817.
69. Yoon K.A., Park J.H., Han J., Park S., Lee G.K., Han J.Y., et al. A Genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population. Hum. Mol. Genet. 2010, 19:4948-4954.
70. Zhou W., Heist R.S., Liu G., Asomaning K., Miller D.P., Neuberg D.S., et al. Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients. Clin. Cancer Res. 2006, 12:7187-7193.